183 related articles for article (PubMed ID: 23306941)
1. Prediction of sustained virologic response based on week 4 and week 12 response in hepatitis C virus genotype 1 patients treated with peginterferon and ribavirin: assessment in a favorable IL28B allele-prevalent area.
Chung HJ; Lee JW; Kim YS; Lee JI
Intervirology; 2013; 56(3):178-83. PubMed ID: 23306941
[TBL] [Abstract][Full Text] [Related]
2. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.
Scherzer TM; Hofer H; Staettermayer AF; Rutter K; Beinhardt S; Steindl-Munda P; Kerschner H; Kessler HH; Ferenci P
J Hepatol; 2011 May; 54(5):866-71. PubMed ID: 21145807
[TBL] [Abstract][Full Text] [Related]
3. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
4. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA
J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783
[TBL] [Abstract][Full Text] [Related]
6. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population.
Rodriguez-Torres M; Sulkowski MS; Chung RT; Hamzeh FM; Jensen DM
J Viral Hepat; 2010 Feb; 17(2):139-47. PubMed ID: 19674282
[TBL] [Abstract][Full Text] [Related]
8. Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.
Dogan UB; Akin MS; Yalaki S
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1317-20. PubMed ID: 23680912
[TBL] [Abstract][Full Text] [Related]
9. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
[TBL] [Abstract][Full Text] [Related]
10. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
11. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
Fattovich G; Covolo L; Bibert S; Askarieh G; Lagging M; Clément S; Malerba G; Pasino M; Guido M; Puoti M; Gaeta GB; Santantonio T; Raimondo G; Bruno R; Bochud PY; Donato F; Negro F;
Aliment Pharmacol Ther; 2011 May; 33(10):1162-72. PubMed ID: 21443535
[TBL] [Abstract][Full Text] [Related]
12. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
[TBL] [Abstract][Full Text] [Related]
13. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
[TBL] [Abstract][Full Text] [Related]
14. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
Mangia A; Thompson AJ; Santoro R; Piazzolla V; Tillmann HL; Patel K; Shianna KV; Mottola L; Petruzzellis D; Bacca D; Carretta V; Minerva N; Goldstein DB; McHutchison JG
Gastroenterology; 2010 Sep; 139(3):821-7, 827.e1. PubMed ID: 20621700
[TBL] [Abstract][Full Text] [Related]
15. Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis c patients treated with peginterferon-alpha2b and ribavirin?
de Segadas-Soares JA; Villela-Nogueira CA; Perez RM; Nabuco LC; Brandão-Mello CE; Coelho HS
J Clin Gastroenterol; 2009 Apr; 43(4):362-6. PubMed ID: 19077732
[TBL] [Abstract][Full Text] [Related]
16. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.
Lin CY; Chen JY; Lin TN; Jeng WJ; Huang CH; Huang CW; Chang SW; Sheen IS
PLoS One; 2011 Mar; 6(3):e18322. PubMed ID: 21479134
[TBL] [Abstract][Full Text] [Related]
17. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
Sperl J; Frankova S; Senkerikova R; Neroldova M; Hejda V; Volfova M; Merta D; Viklicky O; Spicak J; Jirsa M
World J Gastroenterol; 2015 May; 21(18):5496-504. PubMed ID: 25987772
[TBL] [Abstract][Full Text] [Related]
18. Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms.
Ling Q; Chen J; Zhou H; Zhong J; Chen Y; Ye Q; Zhuo Y; Min N; Shang B
Arch Virol; 2015 Apr; 160(4):1105-12. PubMed ID: 25687192
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
20. Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.
Scherzer TM; Stättermayer AF; Strasser M; Laferl H; Maieron A; Stauber R; Datz C; Dulic-Lakovic E; Steindl-Munda P; Hofer H; Ferenci P
Hepatology; 2011 Nov; 54(5):1518-26. PubMed ID: 22006276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]